Astrazeneca (AZN) Profit After Tax (2009 - 2026)

Astrazeneca's Profit After Tax history runs 18 years deep, the most recent figure standing at $3.1 billion for Q1 2026.

• In Q1 2026, Profit After Tax rose 5.48% year-over-year to $3.1 billion; the TTM figure through Mar 2026 stood at $10.4 billion (up 33.55% YoY), while the FY2025 annual figure was $10.2 billion, up 45.33% from the prior year.
• Profit After Tax was $3.1 billion for Q1 2026 at Astrazeneca, up from $2.3 billion in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $3.1 billion in Q1 2026 to a low of $360.0 million in Q2 2022.
• Historically, Profit After Tax has averaged $1.7 billion across 5 years, with a median of $1.8 billion in 2023.
• The sharpest annual moves came in 2022 and 2023: Profit After Tax slumped 68.56% in 2022, then surged 405.56% in 2023.
• A 5-year view of Profit After Tax shows it stood at $902.0 million in 2022, then gained by 6.32% to $959.0 million in 2023, then jumped by 56.41% to $1.5 billion in 2024, then soared by 55.27% to $2.3 billion in 2025, then surged by 32.29% to $3.1 billion in 2026.
• The last three Profit After Tax figures came in at $3.1 billion (Q1 2026), $2.3 billion (Q4 2025), and $2.5 billion (Q3 2025), per Business Quant data.